An open-label phase I/IIa clinical trial of 11β-HSD1 inhibitor for cushing's syndrome and autonomous cortisol secretion
S Oda, K Ashida, M Uchiyama… - The Journal of …, 2021 - academic.oup.com
S Oda, K Ashida, M Uchiyama, S Sakamoto, N Hasuzawa, A Nagayama, L Wang, H Nagata…
The Journal of Clinical Endocrinology & Metabolism, 2021•academic.oup.comContext 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors demonstrate
antimetabolic and antisarcopenic effects in Cushing's syndrome (CS) and autonomous
cortisol secretion (ACS) patients. Objective To confirm the efficacy and safety of S-707106
(11β-HSD1 inhibitor) administered to CS and ACS patients. Design A 24-week single-
center, open-label, single-arm, dose-escalation, investigator-initiated clinical trial on a
database. Setting Kyushu University Hospital, Kurume University Hospital, and related …
antimetabolic and antisarcopenic effects in Cushing's syndrome (CS) and autonomous
cortisol secretion (ACS) patients. Objective To confirm the efficacy and safety of S-707106
(11β-HSD1 inhibitor) administered to CS and ACS patients. Design A 24-week single-
center, open-label, single-arm, dose-escalation, investigator-initiated clinical trial on a
database. Setting Kyushu University Hospital, Kurume University Hospital, and related …
Context
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors demonstrate antimetabolic and antisarcopenic effects in Cushing’s syndrome (CS) and autonomous cortisol secretion (ACS) patients.
Objective
To confirm the efficacy and safety of S-707106 (11β-HSD1 inhibitor) administered to CS and ACS patients.
Design
A 24-week single-center, open-label, single-arm, dose-escalation, investigator-initiated clinical trial on a database.
Setting
Kyushu University Hospital, Kurume University Hospital, and related facilities.
Patients
Sixteen patients with inoperable or recurrent CS and ACS, with mildly impaired glucose tolerance.
Intervention
Oral administration of 200 mg S-707106 after dinner, daily, for 24 weeks. In patients with insufficient improvement in oral glucose tolerance test results at 12 weeks, an escalated dose of S-707106 (200 mg twice daily) was administered for the residual 12 weeks.
Main Outcome Measures
The rate of participants responding to glucose tolerance impairment, defined as those showing a 25% reduction in the area under the curve (AUC) of plasma glucose during the 75-g oral glucose tolerance test at 24 weeks.
Results
S-707106 administration could not achieve the primary endpoint of this clinical trial (>20% of responsive participants). AUC glucose decreased by −7.1% [SD, 14.8 (90% CI −14.8 to −1.0), P = 0.033] and −2.7% [14.5 (−10.2 to 3.4), P = 0.18] at 12 and 24 weeks, respectively. S-707106 administration decreased AUC glucose significantly in participants with a high body mass index. Body fat percentage decreased by −2.5% [1.7 (−3.3 to −1.8), P < 0.001] and body muscle percentage increased by 2.4% [1.6 (1.7 to 3.1), P < 0.001].
Conclusions
S-707106 is an effective insulin sensitizer and antisarcopenic and antiobesity medication for these patients.
Oxford University Press